Uridine has been shown to play a crucial role in modulating the cytotoxic effects of fluoropyrimidines in both normal and tumor tissues. The concentration of uridine in plasma and in tissues is tightly regulated by the activity of uridine phosphorylase (UPase) and by intracellular transport mechanisms. The applicant has utilized inhibition of uridine phosphorylase by benzylacyclouridine (BAU) to elevate uridine concentration in plasma and normal tissues to reduce the toxic effect of 5-fluorouracil (5-FU). During the past few years he has uncovered a series of differences between normal and tumor cells in the control and regulation of uridine levels that can be exploited to achieve more selective cytotoxicity in tumors, better protection of normal tissues that are primary targets of fluoropyrimidine toxicity, and thereby to improve the therapeutic index of 5-fluorouracil. The application focuses on the role of UPase in regulating the intracellular level of uridine in normal versus tumor tissue, on the characterization of this enzyme and its regulation, and on how the presence of a new phosphorolytic activity in human breast tumors can contribute to enhancing the selective rescue of normal tissues while maintaining the cytotoxic effect of fluoropyrimidines in human breast tumors. The proposed studies will also address some critical questions regarding the physiological function of uridine and uridine phosphorylase: 1) why the concentration of uridine in plasma, unlike other nucleosides, is so tightly regulated throughout different species, 2) why the induction of the neoplastic phenotype results directly or indirectly in the elevation of uridine phosphorylase activity, and 3) why breast tumor tissues have a BAU-insensitive, phosphorolytic activity that is not thymidine phosphorylase. To achieve these objectives the research will center on two main projects in progress: isolation and characterization of the protein(s) responsible for the BAU-insensitive phosphorolytic activity present in human breast tumors, and the evaluation of the role of UPase in uridine homeostasis and its effect on 5-FU antitumor therapy. Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA067035-08
Application #
6798808
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Xie, Heng
Project Start
1996-04-01
Project End
2006-08-31
Budget Start
2004-09-01
Budget End
2006-08-31
Support Year
8
Fiscal Year
2004
Total Cost
$185,788
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Cao, Deliang; Ziemba, Amy; McCabe, James et al. (2011) Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. Mol Cancer Ther 10:2330-9
Wan, Laxiang; Cao, Deliang; Zeng, Jianmin et al. (2006) Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells. Mol Pharmacol 69:1389-95
Cao, Deliang; Leffert, Janine J; McCabe, James et al. (2005) Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem 280:21169-75
Pizzorno, Giuseppe; Cao, Deliang; Leffert, Janine J et al. (2002) Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta 1587:133-44
Cao, Deliang; Russell, Rosalind L; Zhang, Dekai et al. (2002) Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62:2313-7
Zhang, D; Cao, D; Russell, R et al. (2001) p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction. Cancer Res 61:6899-905
Cao, D; Nimmakayalu, M A; Wang, F et al. (1999) Genomic structure, chromosomal mapping, and promoter region analysis of murine uridine phosphorylase gene. Cancer Res 59:4997-5001
Liu, M; Cao, D; Russell, R et al. (1998) Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 58:5418-24
Pizzorno, G; Yee, L; Burtness, B A et al. (1998) Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res 4:1165-75